TY - THES A1 - Zimnol, Anna T1 - Relevance of angiotensin II type 1a receptor and NADPH oxidase for the formation of angiotensin II-mediated DNA damage T1 - Relevanz des Angiotensin II Typ 1a-Rezeptors und der NADPH-Oxidase für die Entstehung Angiotensin II-vermittelter DNA-Schäden N2 - Das Renin-Angiotensin-Aldosteron-System (RAAS) reguliert den Blutdruck sowie den Elektrolyt- und Wasserhaushalt. Das aktive Peptid, Angiotensin II (AngII), führt dabei zur Vasokonstriktion und in höheren Konzentrationen zu Bluthochdruck. Hypertensive Patienten haben ein erhöhtes Risiko an Krebs zu erkranken, vor allem an Nierenkrebs. Wir konnten bereits in vivo zeigen, dass AngII in der Lage ist, den Blutdruck zu steigern und dosisabhängig zu DNA-Schäden über den Angiotensin II Typ 1-Rezeptor (AT1R) führt. Ein stimuliertes RAAS kann ferner über die Aktivierung der NADPH-Oxidase, einer Hauptquelle der Generierung reaktiver Sauerstoffspezies (ROS) in der Zelle, zu oxidativem Stress führen. Zielsetzung dieser Arbeit war es zum einen, mit Hilfe von AT1a-Rezeptor-defizienten Mäusen in vivo zu prüfen, ob die Bildung von ROS, sowie die Bildung von DNA-Schäden in der Niere und im Herzen unabhängig von einem erhöhten Blutdruck auftreten. Zum anderen sollte, ebenfalls in vivo, untersucht werden, ob eine oder beide von zwei untersuchten Isoformen der NADPH-Oxidase (Nox) für die Auslösung oxidativen Stresses in der Niere verantwortlich ist. Zunächst wurden für den Versuch zur Überprüfung der Abhängigkeit AngII-induzierter DNA-Schäden vom Blutdruck männliche C57BL/6-Mäuse und AT1a-Knockout (KO)-Mäuse mit osmotischen Minipumpen ausgestattet, die AngII in einer Konzentrationen von 600 ng/kg min über einen Zeitraum von 28 Tagen abgaben. Zusätzlich wurde eine Gruppe von AngII-behandelten Wildtyp (WT)-Mäusen mit dem AT1-Rezeptor-Blocker Candesartan (Cand) behandelt. Während des Versuchszeitraumes fanden regelmäßige, nicht-invasive Blutdruckmessungen an den wachen Mäusen statt. In WT-Mäusen induzierte AngII Bluthochdruck, verursachte erhöhte Albumin-Level im Urin und führte zur Bildung von ROS in Niere und im Herzen. Außerdem traten in dieser Gruppe DNA-Schäden in Form von Einzel- und Doppelstrangbrüchen auf. All diese Reaktionen auf AngII konnten jedoch durch gleichzeitige Behandlung mit Cand verhindert werden. AT1a-KO-Mäuse hatten, verglichen mit WT-Kontrollmäusen, einen signifikant niedrigeren Blutdruck und normale Albumin-Level im Urin. In AT1a-KO-Mäusen, die mit AngII behandelt wurden, konnte kein Anstieg des systolischen Blutdrucks sowie kein Einfluss auf die Nierenfunktion gefunden werden. Jedoch führte AngII in dieser Gruppe zu einer Steigerung von ROS in der Niere und im Herzen. Zusätzlich wurden genomische Schäden, vor allem in Form von Doppelstrangbrüchen signifikant in dieser Gruppe induziert. Auch wenn AT1a-KO-Tiere, unabhängig von einer AngII-Infusion, keine eingeschränkte Nierenfunktion zeigten, so wiesen sie erhebliche histopathologische Schäden im Hinblick auf die Glomeruli und das Tubulussystem auf. Diese Art von Schäden deuten auf eine besondere Bedeutung des AT1aR im Hinblick auf die embryonale Entwicklung der Niere hin. Zusammenfassend beweisen die Ergebnisse dieses Experiments eindeutig, dass eine AngII-induzierte ROS-Produktion und die Induktion von DNA-Schäden unabhängig von einem erhöhten Blutdruck auftreten. Da in der AngII-behandelten AT1a-KO-Gruppe eine signifikant höhere Expression des AT1b-Rezeptors zu finden war und die Blockade von beiden Rezeptorsubtypen mit Cand zu einer Verhinderung der schädlichen Effekte durch AngII führte, scheint der AT1bR im Falle einer AT1aR-Defizienz für die Entstehung der Schäden zuständig zu sein. Ziel des zweiten Experimentes war es, den Beitrag der Nox2 und Nox4 zum oxidativen DNA-Schaden in vivo zu untersuchen. Hierfür wurden männliche C57BL/6-Mäuse und Nox2- oder Nox4-defiziente Mäuse mit osmotischen Minipumpen ausgestattet, die AngII in einer Konzentration von 600 ng/kg min über einen Zeitraum von 28 Tagen abgaben. Im WT-Stamm und in beiden Nox-defizienten Stämmen induzierte AngII Bluthochdruck, verursachte erhöhte Albumin-Level im Urin und führte zur Bildung von ROS in der Niere. Außerdem waren in allen AngII-behandelten Gruppen genomische Schäden, vor allem in Form von Doppelstrangbrüchen, erhöht. Auch in Abwesenheit von AngII wiesen Nox2- und Nox4-defiziente Mäuse mehr Doppelstrangbrüche im Vergleich zu WT-Kontrollmäusen auf. Interessanterweise kompensieren allerdings weder Nox2 noch Nox4 das Fehlen der jeweils anderen Isoform auf RNA-Basis. Aufgrund dieser Ergebnisse schließen wir, dass bislang keine Isoform alleine für die Generierung von oxidativen DNA-Schäden in der Niere verantwortlich gemacht werden kann und dass eine Beteiligung einer weiteren Nox-Isoform sehr wahrscheinlich ist. Möglicherweise könnten aber auch andere ROS-generierende Enzyme, wie Xanthinoxidase oder Stickoxidsynthase involviert sein. Da genomische Schäden in Nieren von Nox2- und Nox4-defizienten Mäusen in Abwesenheit von AngII gegenüber den Schäden in WT-Kontrollmäusen erhöht waren, könnten die beiden Isoformen auch eine schützende Funktion im Bereich von Nierenkrankheiten übernehmen. Da dies aber bislang nur für Nox4 beschrieben ist, ist es wahrscheinlicher, dass das Fehlen von einer der beiden Isoformen eher einen Einfluss auf die Embryonalentwicklung hat. Um dies jedoch abschließend zu klären wäre es sinnvoll mit induzierbaren Knockout-Modellen zu arbeiten, bei denen mögliche entwicklungsbedingte Effekte minimiert werden können. N2 - The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure, electrolyte metabolism and water balance. The reactive peptide, Angiotensin II (AngII), of the RAAS causes vasoconstriction and, in higher concentrations, increased blood pressure. Hypertensive patients have an increased risk to develop cancer, especially kidney cancer. We have shown in vivo, that AngII is capable to cause an elevation of blood pressure, as well as DNA damage dose-dependently via the AngII type 1 receptor (AT1R). A stimulated RAAS can further lead to oxidative stress by activating NADPH oxidases which are major enzymatic sources of reactive oxygen species (ROS) in the cell. On the one hand the aim of this work was to examine in vivo with the help of AT1aR-deficient mice whether the formation of ROS and DNA damage in the kidney and the heart occur independently of an increased blood pressure. On the other hand we wanted to investigate whether one or both of the two examined isoforms of the NADPH oxidase (Nox) is responsible for the triggering of oxidative stress in the kidney. For the purpose of the first experiment which examined the dependency of AngII-induced DNA damage on blood pressure, male C57BL/6-mice and AT1a-knockout (KO)-mice were equipped with osmotic minipumps, delivering AngII in a concentration of 600 ng/kg x min during 28 days. Additionally, wild-type (WT) mice were treated with the AT1R antagonist candesartan (cand). Over the whole time period, frequent non-invasive blood pressure measurements were taken. In WT mice, AngII induced hypertension, an elevated urinary albumin level and formation of ROS in kidney and heart. Furthermore, genomic damage, in form of single- and double strand breaks, was augmented in this group. All these responses to AngII could be attenuated by concurrent administration of candesartan. AT1a-deficient mice had lower basal systolic pressures than WT mice and comparable urinary albumin levels. In AT1a-deficient mice treated with AngII, systolic pressure was not increased, and no effect on renal function could be detected. However, AngII led to an increase of ROS in kidney and heart in this group. In addition, genomic damage, especially in form of double strand breaks was significantly induced. Although AT1a-KO-mice, independent of an AngII-infusion, showed no renal impairment they had significant histopathological changes in glomeruli and tubules. This points to a special importance of AT1aR with regard to the embryonic development of the kidney. In summary our results clearly demonstrate that AngII-induced ROS production and DNA damage is independent of blood pressure. Since we found a significantly higher expression of the AT1bR in the AngII-treated AT1aR-KO-group and since blocking of both subtypes with cand resulted in a complete prevention of adverse AngII effects, the receptor responsible for the mediation of these effects seems to be AT1bR. The aim of the second experiment was to examine the contribution of Nox2 and Nox4 to oxidative DNA damage in vivo. Therefore male C57BL/6-mice and Nox2- or Nox4-deficient mice were equipped with osmotic minipumps, delivering AngII in a concentration of 600 ng/kg × min during 28 days. In WT and in both strains of Nox-deficient mice, AngII induced hypertension, elevated urinary albumin levels and formation of ROS in the kidney. Furthermore, genomic damage, especially in form of double strand breaks were augmented in all of the AngII-treated groups. Also in the absence of AngII, Nox2- and Nox4-deficient mice exhibited a higher background of double strand breaks. Interestingly neither Nox2 nor Nox4 do not compensate for the deficiency of the other isoform on mRNA level. Due to these results we conclude that there is no isoform so far which is solely responsible for the generation of ROS in the kidney under AngII-treatment. Potentially there might also be a contribution of other enzymes like xanthine oxidase or nitric oxide synthase to the formation of ROS. Since genomic damage in kidneys of Nox2- and Nox4-deficient mice in the absence of AngII was higher as compared to the damages in WT control mice it might be that both isoforms could have a protective role in renal disease. But, since this is so far only described for Nox4 it is likely that the absence of one of the two isoforms rather has an influence on the embryonic development. To finally clarify this hypothesis it would be suggestive to work with inducible knockout mouse models where possible developmental effects can be minimized. KW - Angiotensin II KW - NADPH-Oxidase KW - DNS-Schädigung KW - Oxidativer Stress KW - Angiotensin II KW - NADPH oxidase KW - angiotensin II type 1a receptor KW - DNA damage KW - oxidative stress KW - Angiotensin II Typ 1a-Rezeptor Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137469 ER - TY - JOUR A1 - Zimmermann, Henriette A1 - Subota, Ines A1 - Batram, Christopher A1 - Kramer, Susanne A1 - Janzen, Christian J. A1 - Jones, Nicola G. A1 - Engstler, Markus T1 - A quorum sensing-independent path to stumpy development in Trypanosoma brucei JF - PLoS Pathogens N2 - For persistent infections of the mammalian host, African trypanosomes limit their population size by quorum sensing of the parasite-excreted stumpy induction factor (SIF), which induces development to the tsetse-infective stumpy stage. We found that besides this cell density-dependent mechanism, there exists a second path to the stumpy stage that is linked to antigenic variation, the main instrument of parasite virulence. The expression of a second variant surface glycoprotein (VSG) leads to transcriptional attenuation of the VSG expression site (ES) and immediate development to tsetse fly infective stumpy parasites. This path is independent of SIF and solely controlled by the transcriptional status of the ES. In pleomorphic trypanosomes varying degrees of ES-attenuation result in phenotypic plasticity. While full ES-attenuation causes irreversible stumpy development, milder attenuation may open a time window for rescuing an unsuccessful antigenic switch, a scenario that so far has not been considered as important for parasite survival. KW - Trypanosoma KW - hyperexpression techniques KW - parasitic cell cycles KW - cloning KW - cell cycle and cell division KW - cell differentiation KW - tetracyclines KW - parasitic diseases Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158230 VL - 13 IS - 4 ER - TY - JOUR A1 - Ziegler, Sabrina A1 - Weiss, Esther A1 - Schmitt, Anna-Lena A1 - Schlegel, Jan A1 - Burgert, Anne A1 - Terpitz, Ulrich A1 - Sauer, Markus A1 - Moretta, Lorenzo A1 - Sivori, Simona A1 - Leonhardt, Ines A1 - Kurzai, Oliver A1 - Einsele, Hermann A1 - Loeffler, Juergen T1 - CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells JF - Scientific Reports N2 - Aspergillus (A.) fumigatus is an opportunistic fungal mold inducing invasive aspergillosis (IA) in immunocompromised patients. Although antifungal activity of human natural killer (NK) cells was shown in previous studies, the underlying cellular mechanisms and pathogen recognition receptors (PRRs) are still unknown. Using flow cytometry we were able to show that the fluorescence positivity of the surface receptor CD56 significantly decreased upon fungal contact. To visualize the interaction site of NK cells and A. fumigatus we used SEM, CLSM and dSTORM techniques, which clearly demonstrated that NK cells directly interact with A. fumigatus via CD56 and that CD56 is re-organized and accumulated at this interaction site time-dependently. The inhibition of the cytoskeleton showed that the receptor re-organization was an active process dependent on actin re-arrangements. Furthermore, we could show that CD56 plays a role in the fungus mediated NK cell activation, since blocking of CD56 surface receptor reduced fungal mediated NK cell activation and reduced cytokine secretion. These results confirmed the direct interaction of NK cells and A. fumigatus, leading to the conclusion that CD56 is a pathogen recognition receptor. These findings give new insights into the functional role of CD56 in the pathogen recognition during the innate immune response. KW - pattern recognition receptors KW - fungal infection KW - Aspergillus fumigatus KW - natural killer cells Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170637 VL - 7 IS - 6138 ER - TY - JOUR A1 - Wu, Yu A1 - Pons, Valérie A1 - Goudet, Amélie A1 - Panigai, Laetitia A1 - Fischer, Annette A1 - Herweg, Jo-Ana A1 - Kali, Sabrina A1 - Davey, Robert A. A1 - Laporte, Jérôme A1 - Bouclier, Céline A1 - Yousfi, Rahima A1 - Aubenque, Céline A1 - Merer, Goulven A1 - Gobbo, Emilie A1 - Lopez, Roman A1 - Gillet, Cynthia A1 - Cojean, Sandrine A1 - Popoff, Michel R. A1 - Clayette, Pascal A1 - Le Grand, Roger A1 - Boulogne, Claire A1 - Tordo, Noël A1 - Lemichez, Emmanuel A1 - Loiseau, Philippe M. A1 - Rudel, Thomas A1 - Sauvaire, Didier A1 - Cintrat, Jean-Christophe A1 - Gillet, Daniel A1 - Barbier, Julien T1 - ABMA, a small molecule that inhibits intracellular toxins and pathogens by interfering with late endosomal compartments JF - Scientific Reports N2 - Intracellular pathogenic microorganisms and toxins exploit host cell mechanisms to enter, exert their deleterious effects as well as hijack host nutrition for their development. A potential approach to treat multiple pathogen infections and that should not induce drug resistance is the use of small molecules that target host components. We identifed the compound 1-adamantyl (5-bromo-2-methoxybenzyl) amine (ABMA) from a cell-based high throughput screening for its capacity to protect human cells and mice against ricin toxin without toxicity. This compound efciently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA provokes Rab7-positive late endosomal compartment accumulation in mammalian cells without affecting other organelles (early endosomes, lysosomes, the Golgi apparatus, the endoplasmic reticulum or the nucleus). As the mechanism of action of ABMA is restricted to host-endosomal compartments, it reduces cell infection by pathogens that depend on this pathway to invade cells. ABMA may represent a novel class of broad-spectrum compounds with therapeutic potential against diverse severe infectious diseases. KW - biology KW - antimicrobials KW - high-throughput screening KW - infectious diseases Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-173170 VL - 7 ER - TY - JOUR A1 - Wolter, Patrick A1 - Hanselmann, Steffen A1 - Pattschull, Grit A1 - Schruf, Eva A1 - Gaubatz, Stefan T1 - Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy JF - Oncotarget N2 - The MuvB multiprotein complex, together with B-MYB and FOXM1 (MMB-FOXM1), plays an essential role in cell cycle progression by regulating the transcription of genes required for mitosis and cytokinesis. In many tumors, B-MYB and FOXM1 are overexpressed as part of the proliferation signature. However, the transcriptional targets that are important for oncogenesis have not been identified. Given that mitotic kinesins are highly expressed in cancer cells and that selected kinesins have been reported as target genes of MMB-FOXM1, we sought to determine which mitotic kinesins are directly regulated by MMB-FOXM1. We demonstrate that six mitotic kinesins and two microtubule-associated non-motor proteins (MAPs) CEP55 and PRC1 are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cells. Suppression of KIF23 and PRC1 strongly suppressed proliferation of MDA-MB-231 cells. The set of MMB-FOXM1 regulated kinesins genes and 4 additional kinesins which we referred to as the mitotic kinesin signature (MKS) is linked to poor outcome in breast cancer patients. Thus, mitotic kinesins could be used as prognostic biomarker and could be potential therapeutic targets for the treatment of breast cancer. KW - breast cancer KW - kinesin KW - cell cycle KW - cytokinesis Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-171851 VL - 8 IS - 7 ER - TY - JOUR A1 - Wiegering, Armin A1 - Matthes, Niels A1 - Mühling, Bettina A1 - Koospal, Monika A1 - Quenzer, Anne A1 - Peter, Stephanie A1 - Germer, Christoph-Thomas A1 - Linnebacher, Michael A1 - Otto, Christoph T1 - Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin JF - Neoplasia N2 - Colorectal carcinoma (CRC) is the most common cancer of the gastrointestinal tract with frequently dysregulated intracellular signaling pathways, including p53 signaling. The mainstay of chemotherapy treatment of CRC is 5-fluorouracil (5FU) and oxaliplatin. The two anticancer drugs mediate their therapeutic effect via DNA damage-triggered signaling. The small molecule reactivating p53 and inducing tumor apoptosis (RITA) is described as an activator of wild-type and reactivator of mutant p53 function, resulting in elevated levels of p53 protein, cell growth arrest, and cell death. Additionally, it has been shown that RITA can induce DNA damage signaling. It is expected that the therapeutic benefits of 5FU and oxaliplatin can be increased by enhancing DNA damage signaling pathways. Therefore, we highlighted the antiproliferative response of RITA alone and in combination with 5FU or oxaliplatin in human CRC cells. A panel of long-term established CRC cell lines (n = 9) including p53 wild-type, p53 mutant, and p53 null and primary patient-derived, low-passage cell lines (n = 5) with different p53 protein status were used for this study. A substantial number of CRC cells with pronounced sensitivity to RITA (IC\(_{50}\)< 3.0 μmol/l) were identified within established (4/9) and primary patient-derived (2/5) CRC cell lines harboring wild-type or mutant p53 protein. Sensitivity to RITA appeared independent of p53 status and was associated with an increase in antiproliferative response to 5FU and oxaliplatin, a transcriptional increase of p53 targets p21 and NOXA, and a decrease in MYC mRNA. The effect of RITA as an inducer of DNA damage was shown by a strong elevation of phosphorylated histone variant H2A.X, which was restricted to RITA-sensitive cells. Our data underline the primary effect of RITA, inducing DNA damage, and demonstrate the differential antiproliferative effect of RITA to CRC cells independent of p53 protein status. We found a substantial number of RITA-sensitive CRC cells within both panels of established CRC cell lines and primary patient-derived CRC cell lines (6/14) that provide a rationale for combining RITA with 5FU or oxaliplatin to enhance the antiproliferative response to both chemotherapeutic agents. KW - colorectal carcinoma KW - reactivating p53 and inducing tumor apoptosis (RITA) KW - chemotherapy KW - 5-fluorouracil KW - oxaliplatin Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-171067 VL - 19 IS - 4 ER - TY - JOUR A1 - Wegert, Jenny A1 - Vokuh, Christian A1 - Ziegler, Barbara A1 - Ernestus, Karen A1 - Leuschner, Ivo A1 - Furtwängler, Rhoikos A1 - Graf, Norbert A1 - Gessler, Manfred T1 - TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia JF - The Journal of Pathology: Clinical Research N2 - TP53 mutations have been associated with anaplasia in Wilms tumour, which conveys a high risk for relapse and fatal outcome. Nevertheless, TP53 alterations have been reported in no more than 60% of anaplastic tumours, and recent data have suggested their presence in tumours that do not fulfil the criteria for anaplasia, questioning the clinical utility of TP53 analysis. Therefore, we characterized the TP53 status in 84 fatal cases of Wilms tumour, irrespective of histological subtype. We identified TP53 alterations in at least 90% of fatal cases of anaplastic Wilms tumour, and even more when diffuse anaplasia was present, indicating a very strong if not absolute coupling between anaplasia and deregulation of p53 function. Unfortunately, TP53 mutations do not provide additional predictive value in anaplastic tumours since the same mutation rate was found in a cohort of non-fatal anaplastic tumours. When classified according to tumour stage, patients with stage I diffuse anaplastic tumours still had a high chance of survival (87%), but this rate dropped to 26% for stages II–IV. Thus, volume of anaplasia or possible spread may turn out to be critical parameters. Importantly, among non-anaplastic fatal tumours, 26% had TP53 alterations, indicating that TP53 screening may identify additional cases at risk. Several of these non-anaplastic tumours fulfilled some criteria for anaplasia, for example nuclear unrest, suggesting that such partial phenotypes should be under special scrutiny to enhance detection of high-risk tumours via TP53 screening. A major drawback is that these alterations are secondary changes that occur only later in tumour development, leading to striking intratumour heterogeneity that requires multiple biopsies and analysis guided by histological criteria. In conclusion, we found a very close correlation between histological signs of anaplasia and TP53 alterations. The latter may precede development of anaplasia and thereby provide diagnostic value pointing towards aggressive disease. KW - tumour heterogeneity KW - Wilms tumour KW - nephroblastoma KW - anaplasia KW - TP53 Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-158302 VL - 3 ER - TY - JOUR A1 - Wanzek, Katharina A1 - Schwindt, Eike A1 - Capra, John A. A1 - Paeschke, Katrin T1 - Mms1 binds to G-rich regions in Saccharomyces cerevisiae and influences replication and genome stability JF - Nucleic Acids Research N2 - The regulation of replication is essential to preserve genome integrity. Mms1 is part of the E3 ubiquitin ligase complex that is linked to replication fork progression. By identifying Mms1 binding sites genome-wide in Saccharomyces cerevisiae we connected Mms1 function to genome integrity and replication fork progression at particular G-rich motifs. This motif can form G-quadruplex (G4) structures in vitro. G4 are stable DNA structures that are known to impede replication fork progression. In the absence of Mms1, genome stability is at risk at these G-rich/G4 regions as demonstrated by gross chromosomal rearrangement assays. Mms1 binds throughout the cell cycle to these G-rich/G4 regions and supports the binding of Pif1 DNA helicase. Based on these data we propose a mechanistic model in which Mms1 binds to specific G-rich/G4 motif located on the lagging strand template for DNA replication and supports Pif1 function, DNA replication and genome integrity. KW - replication KW - regulation KW - genome integrity KW - Saccharomyces cerevisiae Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170577 VL - 45 IS - 13 ER - TY - THES A1 - Tsoneva, Desislava T1 - Humanized mouse model: a system to study the interactions of human immune system with vaccinia virus-infected human tumors in mice T1 - Humanisiertes Mausmodell: ein System, um die Wechselwirkungen des menschlichen Immunsystems mit Vaccinia-Virus-infizierten humanen Tumoren in Mäusen zu untersuchen N2 - Ein vielversprechender neuer Ansatz zur Behandlung von Krebs beim Menschen ist die Verwendung von onkolytischen Viren, die einen Tumor-spezifischen Tropismus aufweisen. Einer der Top-Kandidaten in diesem Bereich ist das onkolytische Vaccinia Virus (VACV), das bereits vielversprechende Ergebnisse in Tierversuchen und in klinischen Studien gezeigt hat. Aber die von den in vivo in tierischen Modellen erhaltenen Resultate könnten ungenaue Informationen wegen der anatomischen und physiologischen Unterschiede zwischen den Spezies liefern. Andererseits sind Studien in Menschen aufgrund ethischer Erwägungen und potenzieller Toxizität nur limitiert möglich. Die zahlreichen Einschränkungen und Risiken, die mit den Humanstudien verbunden sind, könnten mit der Verwendung eines humanisierten Mausmodells vermieden werden. Die LIVP-1.1.1, GLV-2b372, GLV-1h68, GLV-1h375, GLV-1h376 and GLV-1h377 VACV Stämmen wurden von der Genelux Corporation zur Verfügung gestellt. GLV-2b372 wurde durch Einfügen der TurboFP635 Expressionskassette in den J2R Genlocus des parentalen LIVP-1.1.1-Stammes konstruiert. GLV-1h375, -1h376 and -1h377 kodiert das Gen für den menschlichen CTLA4-blockierenden Einzelketten-Antikörper (CTLA4 scAb). Befunde aus Replikations- and Zytotoxizitätsstudien zeigten, dass alle sechs Viren Tumorzellen infizieren, sich in ihnen replizieren und sie in Zellkultur schließlich ebenso dosis- und zeitabhängig effizient abtöten konnten. CTLA4 scAb und β-Glucuronidase (GusA) Expression sowie Virus Titer in GLV-1h376-infizierten A549-Zellen wurde anhand von ELISA-, β-Glucuronidase- and Standard Plaque-Assays bestimmt. Hierbei zeigte sich eine ausgezeichnete Korrelation mit Korrelationskoeffizienten R2>0.9806. Der durch das GLV-1h376 kodierte CTLA4 scAb wurde erfolgreich aus Überständen von infizierten CV-1-Zellen gereinigt. CTLA4 scAb hat eine hohe in-vitro-Affinität zu seinem menschlichen CTLA4-Zielmolekül sowie abwesende Kreuzreaktivität gegenüber murine CTLA4 gezeigt. CTLA4 scAb Funktionalität wurde in Jurkat-Zellen bestätigt. LIVP-1.1.1, GLV-2b372, GLV-1h68 und GLV-1h376 wurden auch in nicht-tumorösen und/oder tumortragenden humanisierten Mäusen getestet. Zunächst wurde gezeigt, dass die Injektion von menschlichen CD34+ Stammzellen in die Leber von vorkonditionierten neugeborenen NSG Mäusen zu einer erfolgreichen systemische Rekonstitution mit menschlichen Immunzellen geführt hat. CD19+-B-Zellen, CD4+- und CD8+-CD3+-T-Zellen, NKp46+CD56- und NKp46+CD56+-NK-Zellen sowie CD33+-myeloischen Zellen wurden detektiert. Die Mehrheit der nachgewisenen humanen hämatopoetischen Zellen im Mäuseblut in den ersten Wochen nach der Humanisierung waren CD19+-B-Zellen, und nur ein kleiner Teil waren CD3+-T-Zellen. Mit der Zeit wurde eine signifikante Veränderung in CD19+/CD3+-Verhältnis beobachtet, die parallel zur Abnahme der B-Zellen und einem Anstieg der T-Zellen kam. Die Implantation von A549-Zellen unter die Haut dieser Mäuse führte zu einem progressiven Tumorwachstum. Bildgebende Verfahren zur Detektion von Virus-vermittelter TurboFP635- und GFP-Expression, Standard Plaque Assays sowie immunohistochemische Analysen bestätigten die erfolgreiche Invasion der Viren in die subkutanen Tumoren. Die humane CD45+-Zellpopulation in Tumoren wurde hauptsächlich durch NKp46+CD56bright-NK-Zellen und einen hohen Anteil von aktivierten CD4+- und zytotoxische CD8+-T-Zellen dargestellt. Es wurden jedoch keine signifikanten Unterschiede zwischen den Kontroll- und LIVP-1.1.1-infizierten Tumoren beobachtet, was darauf hindeutete, dass die Rekrutierung von NK- und aktivierten T-Zellen, mehr Tumorgewebe-spezifisch als Virus-abhängig waren. Die GLV-1h376-vermittelten CTLA4 scAb-Expression in den infizierten Tumoren war ebenfalls nicht in der Lage, die Aktivierung von Tumor-infiltrierenden T-Zellen im Vergleich zur Kontrolle und GLV-1h68-behandelten Mäusen, signifikant zu erhöhen. ELISA-, β-Glucuronidase- and Standard Plaque-Assays zeigten eine eindeutige Korrelation mit den Korrelationskoeffizienten R2>0,9454 zwischen CTLA4 scAb- und GusA-Konzentrationen und Virus Titer in Tumorproben von GLV-1h376-behandelten Mäusen. T-Zellen, die aus der Milz dieser Tumor-tragenden Mäuse isoliert wurden, waren funktionell und konnten erfolgreich mit Beads aktiviert werden. Mehr CD25+ und IFN-ɣ+ T-Zellen wurden in der GLV-1h376-Gruppe gefunden, wahrscheinlich aufgrund der CTLA4-Blockade durch die Virus-vermittelte CTLA4 scAb-Expression in den Mäusen. Außerdem wurde eine höhere Konzentration von IL-2 in dem Kulturüberstand von diesen Splenozyten im Vergleich zu Kontrollproben nachgewiesen. Im Gegensatz zu der Aktivierung mit Beads konnten T-Zellen von allen drei Maus-Gruppen nicht durch A549 Tumorzellen ex vivo aktiviert werden. Unser Mausmodell hat den besonderen Vorteil, dass sich Tumoren unter der Haut der humanisierten Mäuse entwickeln, was eine genaue Überwachung des Tumorwachstums und Auswertung der onkolytischen Virotherapie ermöglicht. N2 - A promising new approach for the treatment of human cancer is the use of oncolytic viruses, which exhibit tumor tropism. One of the top candidates in this area is the oncolytic vaccinia virus (VACV), which has already shown promising results in animal studies and in clinical trials. However, due to discrepancies in both innate and adaptive immunity between mice and men the evaluation of the vaccinia virus’ interactions with the host immune system in mice are not fully conclusive of what is actually happening in human cancer patients after systemic administration of vaccinia virus. Also, ethical and legal concerns as well as risk of potential toxicity limit research involving human patients. Therefore, a good in vivo model for testing interactions between vaccinia virus and human immune cells, avoiding the numerous limitations and risks associated with human studies, could be a humanized mouse model. LIVP-1.1.1, GLV-2b372, GLV-1h68, GLV-1h375, GLV-1h376 and GLV-1h377 VACVs were provided by Genelux Corporation. GLV-2b372 was constructed by inserting TurboFP635 expression cassette into the J2R locus of the parental LIVP-1.1.1. GLV-1h375, -1h376 and -1h377 VACVs encode the human CTLA4-blocking single-chain antibody (CTLA4 scAb). Performed replication and cytotoxicity assays demonstrated that all six viruses were able to infect, replicate in and kill human tumor cells in virus-dose- and time-dependent fashion. CTLA4 scAb and β-glucuronidase (GusA) expression as well as viral titers in GLV-1h376-infected cells were analyzed by ELISA, β-glucuronidase assay and standard plaque assay, respectively, and compared. An excellent correlation with correlation coefficients R2>0.9806 were observed. GLV-1h376-encoded CTLA4 scAb was successfully purified from supernatants of infected CV-1 cells and demonstrated in vitro affinity to its human CTLA4 target and lack of cross-reactivity to mouse CTLA4. CTLA4 scAb functionality was confirmed in Jurkat cells. LIVP-1.1.1, GLV-2b372, GLV-1h68 and GLV-1h376 were next studied in non-tumorous and/or tumor-bearing humanized mice. It was demonstrated that injection of human CD34+ stem cells into the liver of preconditioned newborn NSG mice let to a successful systemic reconstitution with human immune cells. CD19+ B cells, CD4 and CD8 single positive CD3+ T cell, NKp46+CD56- and NKp46+CD56+ NK cells as well as CD33+ myeloid cells developed. At early time points after engraftment, majority of the human hematopoietic cells detected in the mouse blood were CD19+ B cells and only a small portion were CD3+ T cells. With time a significant change in CD19+/CD3+ ratio was reported with a decrease of B cells and an increase of T cells. Implantation of A549 cells under the skin of those humanized NSG mice resulted in a progressive tumor growth, described for the first time in this thesis. Successful colonization of subcutaneous A549 tumors with VACVs was visualized and demonstrated by detection of virus-mediated TurboFP635 and GFP expression as well as by standard plaque assay and immunohistochemistry. The human CD45+ cell population in tumors was represented mainly by NKp46+CD56bright NK cells and a large portion of activated CD4+ and cytotoxic CD8+ T cells. However, no significant differences were observed between control and LIVP-1.1.1-infected tumors, suggesting that the recruitment of NK and activated T cells were more tumor tissue specific than virus-dependent. Unfortunately, virus-mediated CTLA4 scAb expression in the GLV-1h376-infected tumors was also not able to significantly increase activation of T cells compared to control and GLV-1h68-treated mice. Importantly, ELISA, β-glucuronidase and standard plaque assays showed an excellent correlation with correlation coefficients R2>0.9454 between CTLA4 scAb, GusA concentrations and viral titers in tumor samples from those GLV-1h376 treated mice. T cells isolated from the spleens of such control or GLV-1h68- or -1h376-treated A549 tumor-bearing mice were functional and could successfully be activated with human T cells activation beads. However, although no significant difference was observed between the three mouse groups, a slightly higher percentage of the GLV-1h376-treated mice-derived T cells were expressing CD25 and producing IFN-ɣ after ex vivo activation, probably due to the CTLA4 blockade by the virus-encoded CTLA4 scAb in the GLV-1h376-treated mice. Also, slightly higher levels of IL-2 were detected in the culture supernatant of those splenocytes compared to control samples. In contrast, T cells from all three mouse groups were not able be activated by A549 tumor cells ex vivo. Our model has the specific advantage that tumors develop under the skin of the humanized mice, which allows accurate monitoring of the tumor growth and evaluation of the oncolytic virotherapy. Therefore it is important to choose the right approaches for its further improvement. KW - Vaccinia virus KW - cancer KW - vaccinia virus KW - humanized mice Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-118983 ER - TY - JOUR A1 - Temme, Sebastian A1 - Friebe, Daniela A1 - Schmidt, Timo A1 - Poschmann, Gereon A1 - Hesse, Julia A1 - Steckel, Bodo A1 - Stühler, Kai A1 - Kunz, Meik A1 - Dandekar, Thomas A1 - Ding, Zhaoping A1 - Akhyari, Payam A1 - Lichtenberg, Artur A1 - Schrader, Jürgen T1 - Genetic profiling and surface proteome analysis of human atrial stromal cells and rat ventricular epicardium-derived cells reveals novel insights into their cardiogenic potential JF - Stem Cell Research N2 - Epicardium-derived cells (EPDC) and atrial stromal cells (ASC) display cardio-regenerative potential, but the molecular details are still unexplored. Signals which induce activation, migration and differentiation of these cells are largely unknown. Here we have isolated rat ventricular EPDC and rat/human ASC and performed genetic and proteomic profiling. EPDC and ASC expressed epicardial/mesenchymal markers (WT-1, Tbx18, CD73,CD90, CD44, CD105), cardiac markers (Gata4, Tbx5, troponin T) and also contained phosphocreatine. We used cell surface biotinylation to isolate plasma membrane proteins of rEPDC and hASC, Nano-liquid chromatography with subsequent mass spectrometry and bioinformatics analysis identified 396 rat and 239 human plasma membrane proteins with 149 overlapping proteins. Functional GO-term analysis revealed several significantly enriched categories related to extracellular matrix (ECM), cell migration/differentiation, immunology or angiogenesis. We identified receptors for ephrin and growth factors (IGF, PDGF, EGF, anthrax toxin) known to be involved in cardiac repair and regeneration. Functional category enrichment identified clusters around integrins, PI3K/Akt-signaling and various cardiomyopathies. Our study indicates that EPDC and ASC have a similar molecular phenotype related to cardiac healing/regeneration. The cell surface proteome repository will help to further unravel the molecular details of their cardio-regenerative potential and their role in cardiac diseases. KW - Biology KW - Epicardium-derived cells KW - Human atrial stromal cells KW - Cell surface proteomics Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-172716 VL - 25 ER -